OCALA, Fla., July 18, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, today announced that it received a notice on July 8, 2022, from Jonathan Jorgl (the "Jorgl Notice"), an AIM stockholder who first purchased 1,000 AIM shares on June 27, 2022. The Jorgl Notice seeks to nominate a control slate of two individuals for election to the three-member AIM Board of Directors (the "Board") at the 2022 Annual Meeting of Stockholders (the "Annual Meeting"). The Board has unanimously determined that the Jorgl Notice is invalid due to numerous deficiencies including failure to comply with the Company's bylaws and accordingly has rejected the Jorgl Notice.